ArticleBMC neurology2025
Inflammatory markers and clinical outcomes in acute/subacute severe cerebral venous thrombosis: the role of glucocorticoid therapy.
Article in BMC neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveCerebral venous thrombosis (CVT) presents clinical challenges due to non-specific symptoms and limited biomarkers for assessing severity. Effective treatments for severe CVT are lacking. This study investigates inflammatory biomarkers linked to disease severity and evaluates glucocorticoids' therapeutic potential in severe CVT.
methodsA prospective cohort study of 78 CVT patients assessed disease severity using neurological scores and analyzed inflammatory biomarkers, including hs-CRP, IL-6, neutrophil count, lymphocyte count, and NLR. Changes in severity and biomarkers were evaluated before and after glucocorticoid treatment.
resultsSevere CVT patients had elevated high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6), and neutrophil percentage, with reduced lymphocyte counts compared to non-severe cases. Neutrophil count, NLR, hs-CRP, and IL-6 positively correlated with neurological scores at admission, while lymphocyte percentage showed a negative correlation. Glucocorticoid treatment improved neurological function and reduced hs-CRP and IL-6 levels, suggesting anti-inflammatory benefits.
conclusionNeutrophils, hs-CRP, and IL-6 are promising biomarkers for CVT severity and treatment response. Glucocorticoids may improve outcomes by modulating inflammation, warranting further research into their mechanisms and long-term efficacy in CVT management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.